Home » Newsletters » BioWorld Science

BioWorld Science

June 22, 2016

View Archived Issues

Global Blood begins phase IIa study of GBT-440

National Cancer Institute studies LMB-100 for malignant mesothelioma

FDA grants fast track designation for ProTmune

EMA validates Santhera's MAA for Raxone in Duchenne muscular dystrophy

Immuron and WRAIR collaborate to develop Shigella vaccine

Curis doses the first patient in phase I trial of CA-170

FDA grants orphan drug designation for Wave Life Sciences' Huntington's disease candidate

Phase II trial of Frontier's AB-001 patch in chronic low back pain meets primary endpoint

Chugai and Maruho launch Marduox combination topical ointment for psoriasis vulgaris

AbbVie presents phase I results for ABT-165

Axon initiates phase II trial of AADvac-1 for Alzheimer's disease

Cancer Research Technology announces PARG inhibitors

Natco Pharma discloses antineoplastic agents

Pfizer introduces AMPK activators

TB Alliance and Takeda sign agreement to explore hits from TB screening program

Channel Therapeutics divulges imidazolyl-phenanthroline derivatives

Ferrer acquires Alexza Pharmaceuticals

RedHill Biopharma reports results from phase I study of Yeliva

Unique collaboration to translate stem cell discoveries into novel treatments for diabetes

GC-1118 shows antitumor activity in colorectal cancer

FDA grants fast track designation to Oncternal's TK-216

OctreoPharm Sciences diagnostic [68Ga]OPS-202 more sensitive than comparator in clinical trial

Japanese orphan drug designation for selexipag for chronic thromboembolic pulmonary hypertension

New GPR120 agonist shows promise for type 2 diabetes

GO-FURTHER data demonstrate golimumab improves hemoglobin levels and anemia

EnBiotix antibiotic-potentiator products EBX-001, EBX-002 show preclinical activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...